Clinical Trial Update: Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of first-line docetaxel plus pemetrexed in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Taxotere (docetaxel)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED